Corrigendum: Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference
Sunbeom Kwon, Suji Jeong, Seulah Lee
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGinkgo biloba and Cashew Applications · Magnolia and Illicium research · Pharmacogenetics and Drug Metabolism
In the published article, references 27 and 28 were cited in the Conclusion section. Due to the text correction listed below, these citations have been removed.
In the published article, there is an erroneous statement in the Conclusion section: “The potential inhibitory effects of PCA on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 have been reported based on molecular docking simulations [27]. In particular, in vivo animal studies have demonstrated that PCA inhibits the enzymatic activity of CYP1A2 and CYP2E1 [28]. On the basis of prior research, it is reasonable to hypothesize that the enhanced CYP inhibition observed in EGb 761®, A4, and B2 is associated with their high concentrations of PCA.”
The correct statement is “While a direct causal relationship between reduced CYP inhibitory activity and PCA could not be definitively confirmed–due to the presence of numerous other compounds in EGb 761® and other raw materials or final drug products–further research is needed to clarify this relationship, as the chemical composition of G. biloba extracts is well-documented.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.